Investor Presentaiton

Investor presentation Full year 2018 Slide 7 OzempicⓇ gains market share and is now launched in 11 countries USA GLP-1 NBRX market share Canada GLP-1 NBRX market share European¹ GLP-1 volume market share albiglutide NN GLP-1 Victoza® OzempicⓇ dulaglutide exenatide Weekly NBRx share Monthly NBRX share Monthly volume share 50% 48.3% 100% 100% 81.4% 40% 80% 80% 40.8% 30% 60% 60% 25.7% 50.7% 20% 40% 40% 22.6% 30.7% 10% 10.8% 20% 20% 18.0% 0% 0% 0% Jan 2018 Jan 2019 Jan 2018 Oct 2018 Jan 2018 Source: NBRX-IQVIA LRX Weekly, week ending 13 Jan 2019 Ozempic® has been launched in: the USA, Canada, Denmark, Switzerland, Ireland, Sweden, the Netherlands, Iceland, the UK, Norway and Finland Source: NBRX-IQVIA monthly, Oct 2018 81.1% 71.5% 15.8% 9.6% Nov 2018 Source: IQVIA monthly, Nov 2018 1 Markets include: Denmark, Switzerland, Ireland, Sweden and the Netherlands

View entire presentation